Article Details

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84 ...

Retrieved on: 2021-07-09 15:56:15

Tags for this article:

Click the tags to see associated articles and topics

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84 .... View article details on hiswai:

Excerpt

LUND, Sweden, July 9, 2021 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up